Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Pfizer Inc (PFE) Price & Performance

NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.00, up 4.77% in the last 24 hours. The technical outlook is bullish, supported by moving averages, though the RSI suggests mild overbought conditions. Recent corporate actions include two stock splits effective June 2026. The fund provides leveraged exposure to NVIDIA, which remains a dominant force in AI, but key financial ratios for NVDL itself are not publicly detailed as it is an ETF tracking daily returns.

The outlook for NVDL hinges on NVIDIA's performance, with bullish technicals and media sentiment pointing to potential gains, especially around earnings. However, risks include high volatility from daily leverage reset, which can amplify losses during NVIDIA downturns, as seen in past sharp declines. Investors should weigh the leveraged structure's compounding effects against NVIDIA's strong AI-driven growth trajectory.

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.